Current Report · Items 5.07 · 8-K/A
Avita Medical, Inc.
Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. As previously disclosed in the Original Form 8-K, at the Meeting the Company's stockholders cast the following votes on an advisory basis regarding the frequency of future advisory votes on the compensation of the Company's named executive officers: 8. Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation (Proposal 13):…
Filed Aug 6, 2026Accepted Aug 6, 2026, 4:25 PM EDTCIK 1762303Accession 0001193125-26-338135
Company context
AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is RECELL®, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute Cohealyx®, an AVITA Medical-branded collagen-based dermal matrix, and the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix.
Current securities
Disclosure sections
Items 5.07Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07 Submission of Matters to a Vote of Security Holders.
As previously disclosed in the Original Form 8-K, at the Meeting the Company's stockholders cast the following votes on an advisory basis regarding the frequency of future advisory votes on the compensation of the Company's named executive officers:
8.
Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation (Proposal 13): Stockholders voted in favor of the non-binding advisory vote to set the frequency of future advisory votes to approve the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows:
Votes For
1 Year 2 Years 3 Years Abstentions Broker Non-Votes
9,545,151 924,743 650,252 581,759 3,890,542
Consistent with the recommendation of the Company's Board of Directors and the option receiving the highest number of votes cast by the Company's stockholders, the Board of Directors has determined that the Company will hold future advisory votes on the compensation of its named executive officers every year until the next required advisory vote on the frequency of such votes, which will occur no later than the Company's 2032 Annual Meeting of Stockholders.